Literature DB >> 9599334

Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions.

I Mews1, M Bergmann, S Bunkowski, F Gullotta, W Brück.   

Abstract

Oligodendrocyte and axon pathology was studied in 11 autopsy cases of clinically silent multiple sclerosis. A total of 54 lesions, either demyelinated or late remyelinated, were distributed through the whole brain and spinal cord with 39% of the lesions located in periventricular areas. Determination of axon density revealed an average reduction of 64% and 59% in demyelinated and remyelinated lesions with an extreme variation between different plaques and cases. Oligodendrocytes were identified by immunocytochemistry for myelin oligodendrocyte glycoprotein (MOG) and in situ hybridization for proteolipid protein (PLP) mRNA. Oligodendrocytes were almost completely lost in demyelinated lesions; remyelinated lesions revealed preservation of a considerable number of oligodendrocytes within the lesions. At the border between plaques and the periplaque white matter, similar oligodendrocyte numbers as in remyelinated lesions were found. Different factors including lesion site, axonal preservation and remyelination may thus contribute to the clinical nonappearance of multiple sclerosis lesions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9599334     DOI: 10.1177/135245859800400203

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  31 in total

1.  Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome.

Authors:  D T Okuda; E M Mowry; B A C Cree; E C Crabtree; D S Goodin; E Waubant; D Pelletier
Journal:  Neurology       Date:  2011-01-26       Impact factor: 9.910

Review 2.  Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis.

Authors:  Kelly A Chamberlain; Sonia E Nanescu; Konstantina Psachoulia; Jeffrey K Huang
Journal:  Neuropharmacology       Date:  2015-10-22       Impact factor: 5.250

3.  Absence of perforin expression confers axonal protection despite demyelination.

Authors:  Charles L Howe; Jaimie D Adelson; Moses Rodriguez
Journal:  Neurobiol Dis       Date:  2006-11-16       Impact factor: 5.996

4.  Veins in plaques of multiple sclerosis patients - a longitudinal magnetic resonance imaging study at 7 Tesla.

Authors:  Assunta Dal-Bianco; Simon Hametner; Günther Grabner; Melanie Schernthaner; Claudia Kronnerwetter; Andreas Reitner; Clemens Vass; Karl Kircher; Eduard Auff; Fritz Leutmezer; Karl Vass; Siegfried Trattnig
Journal:  Eur Radiol       Date:  2015-04-23       Impact factor: 5.315

Review 5.  The role of glial-neuronal metabolic cooperation in modulating progression of multiple sclerosis and neuropathic pain.

Authors:  Rachel R Robinson; Alina K Dietz; Asif M Maroof; Reto Asmis; Thomas G Forsthuber
Journal:  Immunotherapy       Date:  2019-02       Impact factor: 4.196

Review 6.  The pathology of multiple sclerosis is the result of focal inflammatory demyelination with axonal damage.

Authors:  Wolfgang Brück
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

7.  MTR recovery in brain lesions in the BECOME study of glatiramer acetate vs interferon β-1b.

Authors:  Robert A Brown; Sridar Narayanan; Nikola Stikov; Stuart Cook; Diego Cadavid; Leo Wolansky; Douglas L Arnold
Journal:  Neurology       Date:  2016-07-29       Impact factor: 9.910

Review 8.  Review: Mitochondria and disease progression in multiple sclerosis.

Authors:  D Mahad; H Lassmann; D Turnbull
Journal:  Neuropathol Appl Neurobiol       Date:  2008-12       Impact factor: 8.090

9.  Axonal degeneration and progressive neurologic disability in multiple sclerosis.

Authors:  Carl Bjartmar; Bruce D Trapp
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 10.  New concepts on progressive multiple sclerosis.

Authors:  Hans Lassmann
Journal:  Curr Neurol Neurosci Rep       Date:  2007-05       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.